Search Results - "PAPALDO, P"

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine by Metro, G., Foglietta, J., Russillo, M., Stocchi, L., Vidiri, A., Giannarelli, D., Crinò, L., Papaldo, P., Mottolese, M., Cognetti, F., Fabi, A., Gori, S.

“…In the present study, we investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive…”
Get full text

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease by Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A.M., Di Cocco, B., Pino, M.S., Carlini, P., Di Cosimo, S., Sacchi, I., Sperduti, I., Nardoni, C., Cognetti, F.

“…Purpose: To observe whether in pretreated metastatic breast cancer patients with HER2-positive disease vinorelbine plus trastuzumab can produce different…”
Get full text

Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number by Ferretti, G, Papaldo, P

Get full text

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer by Di Cosimo, S., Alimonti, A., Ferretti, G., Sperduti, I., Carlini, P., Papaldo, P., Fabi, A., Gelibter, A., Ciccarese, M., Giannarelli, D., Mandalà, M., Milella, M., Ruggeri, E. M., Cognetti, F.

“…Background: The aim of this study was to characterize the factors associated with chemotherapy-induced amenorrhea (CIA) and to examine whether the phase of the…”
Get full text

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials by FERRETTI, G, BRIA, E, CECERE, F. L, GELIBTER, A, NUZZO, C, COGNETTI, F, TERZOLI, E, CARLINI, P, GIANNARELLI, D, FELICI, A, PAPALDO, P, FABI, A, DI COSIMO, S, RUGGERI, E. M, MILELLA, M, CICCARESE, M

“…The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB), time to progression…”
Get full text

Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow? by Fabi, A., Vidiri, A., Ferretti, G., Felici, A., Papaldo, P., Carlini, P., Mirri, A., Nuzzo, C., Cognetti, F.

“…Several chemotherapic agents, which are active againstbreast cancer, penetrate poorly into the central nervous system. Despite its limited brain penetration,…”
Get full text

Gastric metastasis of breast carcinoma 9 years after mastectomy by Covello, R, Morelli, L, Papaldo, P, Grassi, A, Licci, S

Get more information

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL by Di Costanzo, F., Gasperoni, S., Papaldo, P., Bilancia, D., Manzione, L., Landucci, E., Mazzoni, F., Cognetti, F.

“…Background: Paclitaxel and capecitabine have demonstrated a synergic effect and significant antitumor activity in patients with advanced breast cancer. A…”
Get full text

Does low-molecular-weight heparin influence cancer-related mortality? by Ferretti, G, Bria, E, Giannarelli, D, Carlini, P, Felici, A, Mandalà, M, Papaldo, P, Fabi, A, Ciccarese, M, Cognetti, F

Get full text

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable? by Carlini, P., Frassoldati, A., De Marco, S., Casali, A., Ruggeri, E. M., Nardi, M., Papaldo, P., Fabi, A., Paoloni, F., Cognetti, F.

“…Summary Background There are few clinical data on the sequential use of aromatase inhibitors (Al) This paper focuses on the relevance of clinical benefit CB…”
Get full text

Chemotherapy-induced amenorrhea in early breast cancer by Ferretti, G., Carlini, P., Bria, E., Felici, A., Giannarelli, D., Ciccarese, M., Papaldo, P., Fabi, A., Cognetti, F.

Get full text

Molecular stool testing for the early detection of colorectal cancer: swan song for p53? by Ferretti, G., Felici, A., Ciccarese, M., Papaldo, P., Carlini, P., Fabi, A., Gelibter, A., Cognetti, F.

Get full text

Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women? by Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A., Ruggeri, E. M., Alimonti, A., Nardoni, C., Cognetti, F.

Get full text

Zoledronic acid-associated thrombotic thrombocytopenic purpura by Ferretti, G., Petti, M. C., Carlini, P., Zeuli, M., Picardi, A., Meloni, G., Bria, E., Papaldo, P., Fabi, A., Cognetti, F.

Get full text

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden? by Ferretti, G., Bria, E., Felici, A., Carlini, P., Giannarelli, D., Ciccarese, M., Papaldo, P., Fabi, A., Gelibter, A., Cognetti, F.

Get full text

Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury? by Ferretti, G., Mandalà, M., Bria, E., Papaldo, P., Carlini, P., Fabi, A., Milella, M., Ruggeri, E.M., Nisticò, C., Cognetti, F.

Get full text

Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients? by Fabi, A., Ferretti, G., Salesi, N., Papaldo, P., Carlini, P., Ciccarese, M., Di Cocco, B., Cecere, F., Nardoni, C., Felici, A., Cognetti, F.

Get full text

Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening? by Ferretti, G, Bria, E, Carlini, P, Felici, A, Giannarelli, D, Cuppone, F, Papaldo, P, Nisticò, C, Fabi, A, Gelibter, A, Terzoli, E, Cognetti, F

“…[...]colonoscopy could have produced false negative results for several reasons, including misinterpretation of what was visualised or failure to perform…”
Get full text

Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin by Carlini, P., Di Cosimo, S., Ferretti, G., Papaldo, P., Fabi, A., Ruggeri, E. M., Milella, M., Cognetti, F.

Get full text

Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients by Venturini, M., Michelotti, A., Papaldo, P., Mastro, L. Del, Bergaglio, M., Lionetto, R., Lunardi, G., Sguotti, C., Frevola, L., Donati, S., Rosso, R., Cognetti, F.

“…Purpose: To determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of docetaxel in combination with fixed doses of epirubicin…”
Get full text